Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2021 | Advancing CAR-T in multiple myeloma

Andrew Cowan • 11 Dec 2021
ASH 2021
Multiple Myeloma CAR-T

Andrew Cowan, MD, University of Washington, Seattle, WA, discusses how the use of CAR T-cell therapy is likely to advance in the coming years, commenting on the need for better management of toxicities and improved patient access. This interview took place at during 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

More from Andrew Cowan

Novel targets being explored in multiple myeloma and the value of CELMoDs 1:33
Novel targets being explored in multiple myeloma and the value of CELMoDs
Andrew Cowan • 29 Sep 2023
Improving manufacturing of CAR-T cells in multiple myeloma: PHE885 & other novel constructs 1:24
Improving manufacturing of CAR-T cells in multiple myeloma: PHE885 & other novel constructs
Andrew Cowan • 29 Sep 2023
Phase I trial evaluating a gamma secretase inhibitor in combination with CAR-T cells in R/R myeloma 1:53
Phase I trial evaluating a gamma secretase inhibitor in combination with CAR-T cells in R/R myeloma
Andrew Cowan • 29 Sep 2023
Real-world analysis of patients with R/R myeloma treated with lenalidomide & an anti-CD38 mAb 1:47
Real-world analysis of patients with R/R myeloma treated with lenalidomide & an anti-CD38 mAb
Andrew Cowan • 29 Sep 2023

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals